A detailed history of Mercer Global Advisors Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mercer Global Advisors Inc holds 15,551 shares of VRTX stock, worth $7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
15,551
Previous 16,503 5.77%
Holding current value
$7 Million
Previous $7.74 Million 6.5%
% of portfolio
0.02%
Previous 0.02%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $437,920 - $481,502
-952 Reduced 5.77%
15,551 $7.23 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $1.22 Million - $1.51 Million
3,106 Added 23.18%
16,503 $7.74 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $456,205 - $499,163
-1,119 Reduced 7.71%
13,397 $5.6 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $956,627 - $1.15 Million
2,789 Added 23.78%
14,516 $5.91 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $241,122 - $258,433
713 Added 6.47%
11,727 $4.08 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $282,663 - $316,367
899 Added 8.89%
11,014 $3.88 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $515,761 - $588,365
1,821 Added 21.96%
10,115 $3.19 Million
Q4 2022

Feb 08, 2023

BUY
$285.76 - $321.48 $48,579 - $54,651
170 Added 2.09%
8,294 $2.4 Million
Q3 2022

Nov 15, 2022

SELL
$273.83 - $305.53 $228,648 - $255,117
-835 Reduced 9.32%
8,124 $2.35 Million
Q2 2022

Aug 10, 2022

SELL
$234.96 - $292.55 $264,799 - $329,703
-1,127 Reduced 11.17%
8,959 $2.53 Million
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $135,730 - $159,974
613 Added 6.47%
10,086 $2.63 Million
Q4 2021

Feb 04, 2022

BUY
$177.01 - $223.45 $398,449 - $502,985
2,251 Added 31.17%
9,473 $2.08 Million
Q3 2021

Nov 10, 2021

BUY
$181.39 - $202.99 $147,651 - $165,233
814 Added 12.7%
7,222 $1.31 Million
Q2 2021

Aug 10, 2021

SELL
$187.49 - $221.1 $2.14 Million - $2.52 Million
-11,397 Reduced 64.01%
6,408 $1.29 Million
Q1 2021

Aug 10, 2021

BUY
$207.02 - $241.31 $2.92 Million - $3.41 Million
14,117 Added 382.78%
17,805 $3.83 Million
Q1 2021

May 11, 2021

SELL
$207.02 - $241.31 $303,284 - $353,519
-1,465 Reduced 28.43%
3,688 $793,000
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $341,773 - $455,824
-1,651 Reduced 24.27%
5,153 $1.22 Million
Q3 2020

Dec 10, 2020

BUY
$255.65 - $303.1 $175,631 - $208,229
687 Added 11.23%
6,804 $1.85 Million
Q2 2020

Aug 10, 2020

BUY
$225.48 - $295.8 $1.05 Million - $1.38 Million
4,667 Added 321.86%
6,117 $1.78 Million
Q1 2020

May 18, 2020

SELL
$199.77 - $247.81 $9,389 - $11,647
-47 Reduced 3.14%
1,450 $345,000
Q4 2019

Feb 13, 2020

SELL
$166.71 - $223.91 $1,667 - $2,239
-10 Reduced 0.66%
1,497 $328,000
Q3 2019

Nov 12, 2019

BUY
$166.23 - $187.09 $8,145 - $9,167
49 Added 3.36%
1,507 $255,000
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $4,773 - $5,520
29 Added 2.03%
1,458 $267,000
Q1 2019

Apr 23, 2019

BUY
$163.73 - $194.7 $20,466 - $24,337
125 Added 9.59%
1,429 $263,000
Q1 2019

Apr 12, 2019

BUY
$163.73 - $194.7 $213,503 - $253,888
1,304 New
1,304 $216,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.